Abstract:Background Metabolic associated fatty liver disease (MAFLD) is a novel terminology introduced in 2020 to provide a more accurate description of fatty liver disease associated with metabolic dysfunction. It replaces the outdated term nonalcoholic fatty liver disease (NAFLD) and aims to improve diagnostic criteria and tailored treatment strategies for the disease. NAFLD, the most prevalent liver disease in western industrialized nations, has been steadily increasing in prevalence and is associated with serious complications such as cirrhosis and hepatocellular carcinoma. It is also linked to insulin resistance syndrome and cardiovascular diseases. However, current studies on NAFLD have limitations in meeting necessary histological endpoints. Objective This literature review aims to consolidate recent knowledge and discoveries concerning MAFLD, integrating the diverse aspects of the disease. Specifically, it focuses on analyzing the diagnostic criteria for MAFLD, differentiating it from NAFLD and alcoholic fatty liver disease (AFLD), and exploring the epidemiology, clinical manifestations, pathogenesis, and management approaches associated with MAFLD. The review also explores the associations between MAFLD and other conditions. It discusses the heightened mortality risk associated with MAFLD and its link to chronic kidney disease (CKD), showing that MAFLD exhibits enhanced diagnostic accuracy for identifying patients with CKD compared to NAFLD. The association between MAFLD and incident/prevalent CKD is supported by cohort studies and meta-analyses. Conclusion This literature review highlights the importance of MAFLD as a distinct terminology for fatty liver disease associated with metabolic dysfunction. The review provides insights into the diagnostic criteria, associations with CKD, and management approaches for MAFLD. Further research is needed to develop more accurate diagnostic tools for advanced fibrosis in MAFLD and to explore the underlying mechanisms linking MAFLD with other conditions. This review serves as a valuable resource for researchers and healthcare professionals seeking a comprehensive understanding of MAFLD.

Altered lipid metabolism and the development of metabolic-associated fatty liver disease

Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease

Lipid Disorders and Metabolic-Associated Fatty Liver Disease

Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways

Home hospitalization unit: an alternative to standard inpatient hospitalization from the emergency department

Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies

Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight

Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease

Metabolic dysfunction associated fatty liver disease in healthy weight individuals

A transducer for intra-uterine fetal phonocardiography

Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals

Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

In vitro reductive activation of nitroimidazoles.

MAFLD: a multisystem disease

MAFLD as part of systemic metabolic dysregulation

Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact

Metabolic associated fatty liver disease increases risk of adverse events after acute coronary syndrome

Innate immunity and nonalcoholic fatty liver disease

Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention

Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease